Eso Masterclass In Neuro-Oncology: Multidisciplinary Management Of Adult Brain Tumour

September 20 — September 22

Milan, Italy

Programme

The European School of Oncology was founded by Umberto Veronesi and Laudomia Del Drago in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the learning process, and the goal of caring for the patient in a holistic sense, in contrast to focusing purely on treating the disease.

Due to its financial independence, ESO has the rare privilege of being able to set its own priorities. It therefore pays particular attention to developing the transfer of knowledge in areas that are least supported by industry, such as surgery and in rare pathologies (including childhood tumours), and in countries and regions with limited economic resources.

Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications

The definitive textbook on state-of-the-art fluorescence-guided neurosurgery

Advances in fluorescence-guided surgery (FGS) have resulted in a paradigm shift in neurosurgical approaches to neuro-oncological and cerebrovascular pathologies. Edited by two of the foremost authorities on the topic, Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications encompasses the depth and breadth of this groundbreaking, still nascent technology. The book reflects significant contributions made by world renowned neurosurgeons Constantinos Hadjipanayis, Walter Stummer, and esteemed contributors on the growing uses of 5-aminolevulinic acid (5-ALA) and other FGS agents.

The European Medicine Agency approved 5-ALA in 2007, heralding the birth of FGS globally. In 2017, the U.S. Food and Drug Administration approved 5-ALA (Gleolan) as an imaging agent to facilitate realtime detection and visualization of malignant tissue during glioma surgery. In the two decades since Dr. Stummer’s initial description of 5-ALA FGS in a human patient, major strides have been made in its practical applications, leading to improved resection outcomes. As FGS is increasingly incorporated into neurosurgical practice, it holds promise for future innovations. Generously-illustrated and enhanced with online videos, this textbook is the definitive resource on the subject.

Key Features

  • The improved efficacy of 5-ALA for resecting high- and low-grade gliomas, recurrences, meningiomas, brain metastases, spinal cord tumors, pediatric brain tumors, and other adult tumors
  • The future of fluorescence, including potentially powerful new fluorophores molecularly targeted specifically to tumors
  • The use of the fluorescent agent indocyanine green (ICG) for brain tumors, cerebral aneurysms, AVMs, and cerebral vascularization
  • Special topics such as fluorescein, illuminating tumor paint, confocal microscopy, Raman spectroscopy, and integrating FGS with intraoperative imaging and brain mapping

This single accessible reference presents the current state-of-the-art on this emerging, exciting surgical technology. As such, it is a must-have for neurosurgical residents, fellows, and practicing neurosurgeons.

 

 

4th Pediatric Neuro-Oncology Basic and Translational Research Conference

4th Pediatric Neuro-Oncology Basic and Translational Research Conference

June 15 — June 16

New York, NY, USA
Hosted by the Society for Neuro-Oncology, taking place at the Wyndham New Yorker Hotel in New York, New York.
Website: http://www.soc-neuro-onc.org/pediatric-neurooncology-research-conference/

Neuro-Oncology January 2017

1: Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S,
Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune
resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jan 23.
pii: now287. doi: 10.1093/neuonc/now287. [Epub ahead of print] PubMed PMID:
28115578.
2: Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF,
Schumacher SE, O’Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A,
Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H,
Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE,
Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM,
Chi SN, Beroukhim R, Ligon KL. Clinical targeted exome-based sequencing in
combination with genome-wide copy number profiling: precision medicine analysis
of 203 pediatric brain tumors. Neuro Oncol. 2017 Jan 19. pii: now294. doi:
10.1093/neuonc/now294. [Epub ahead of print] PubMed PMID: 28104717.
3: Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B,
Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M. Combining
standard clinical blood values for improving survival prediction in patients with
newly diagnosed brain metastases-development and validation of the LabBM score.
Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093/neuonc/now290. [Epub ahead of
print] PubMed PMID: 28096493.
4: Altinoz MA, Guloksuz S, Elmaci I. Rabies virus vaccine as an immune adjuvant
against cancers and glioblastoma: new studies may resurrect a neglected
potential. Clin Transl Oncol. 2017 Jan 16. doi: 10.1007/s12094-017-1613-6. [Epub
ahead of print] Review. PubMed PMID: 28093702.
5: Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH,
Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW,
Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA,
Stiles CD. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF
oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 Jan 12. pii:
now261. doi: 10.1093/neuonc/now261. [Epub ahead of print] PubMed PMID: 28082416.
6: Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M. SMO mutation status
defines a distinct and frequent molecular subgroup in olfactory groove
meningiomas. Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093/neuonc/now276.
[Epub ahead of print] PubMed PMID: 28082415.
7: Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT,
Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in
patient-derived glioblastoma culture models. Neuro Oncol. 2017 Jan 6. pii:
now253. doi: 10.1093/neuonc/now253. [Epub ahead of print] PubMed PMID: 28062830.
8: Zhu C, Mustafa D, Zheng PP, van der Weiden M, Sacchetti A, Brandt M, Chrifi I,
Tempel D, Leenen PJ, Duncker DJ, Cheng C, Kros JM. Activation of CECR1 in M2-like
TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro
Oncol. 2017 Jan 3. pii: now251. doi: 10.1093/neuonc/now251. [Epub ahead of print]
PubMed PMID: 28053137.
9: Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H. The
etiopathogenesis of diffuse low-grade gliomas. Crit Rev Oncol Hematol. 2017
Jan;109:51-62. doi: 10.1016/j.critrevonc.2016.11.014. Review. PubMed PMID:
28010898.
10: Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in
epigenetics (Review). Oncol Rep. 2017 Jan;37(1):3-9. doi: 10.3892/or.2016.5236.
PubMed PMID: 27841002.
11: Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen
PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J,
MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis
LM. Seizure control as a new metric in assessing efficacy of tumor treatment in
low-grade glioma trials. Neuro Oncol. 2017 Jan;19(1):12-21. doi:
10.1093/neuonc/now190. Review. PubMed PMID: 27651472; PubMed Central PMCID:
PMC5193028.
12: Guidi M, Giunti L, Lucchesi M, Scoccianti S, Giglio S, Favre C, Oliveri G,
Sardi I. Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a
gliosarcoma patient. Future Oncol. 2017 Jan;13(1):9-12. PubMed PMID: 27523101.
13: Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck
AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins
RB, Sicotte H, Kollmeyer TM, O’Neill BP, Elmquist W, Hoxworth JM, Frakes D,
Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR. Radiogenomics to characterize
regional genetic heterogeneity in glioblastoma. Neuro Oncol. 2017
Jan;19(1):128-137. doi: 10.1093/neuonc/now135. PubMed PMID: 27502248; PubMed
Central PMCID: PMC5193022.
14: Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a
malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro
Oncol. 2017 Jan;19(1):55-65. doi: 10.1093/neuonc/now129. PubMed PMID: 27471108;
PubMed Central PMCID: PMC5193021.
15: Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E,
Berendsen S, Dedobbeleer M, Willems E, Robe P, Bours V, Martin D, Martinive P,
Maquet P, Rogister B. CXCL12 mediates glioblastoma resistance to radiotherapy in
the subventricular zone. Neuro Oncol. 2017 Jan;19(1):66-77. doi:
10.1093/neuonc/now136. PubMed PMID: 27370398; PubMed Central PMCID: PMC5193023.
16: Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL,
Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate
dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017
Jan;19(1):109-117. doi: 10.1093/neuonc/now121. PubMed PMID: 27353503; PubMed
Central PMCID: PMC5193019.

Book: Handbook of Neuro-Oncology Neuroimaging, Second Edition

Handbook of Neuro-Oncology Neuroimaging, Second Edition

Handbook of Neuro-Oncology Neuroimaging, Second Edition
Price: $210.00
ADD TO SHOPPING CART
Remarkable progress in neuro-oncology due to increased utilization of advanced imaging in clinical practice continues to accelerate in recent years. Refinements in magnetic resonance imaging (MRI) and computed tomography (CT) technology, and the addition of newer anatomical, functional, and metabolic imaging methods, such as MRS, fMRI, diffusion MRI, and DTI MRI have allowed brain tumor patients to be diagnosed much earlier and to be followed more carefully during treatment. With treatment approaches and the field of neuro-oncology neuroimaging changing rapidly, this second edition of the Handbook of Neuro-Oncology Neuroimaging is so relevant to those in the field, providing a single-source, comprehensive, reference handbook of the most up-to-date clinical and technical information regarding the application of neuro-Imaging techniques to brain tumor and neuro-oncology patients. This new volume will have updates on all of the material from the first edition, and in addition will feature several new important chapters covering diverse topics such as advanced imaging techniques in radiation therapy, therapeutic treatment fields, response assessment in clinical trials, surgical planning of neoplastic disease of the spine, and more. It will also serve as a resource of background information to neuroimaging researchers and basic scientists with an interest in brain tumors and neuro-oncology.

  • Provides a background to translational research and the use of brain imaging for brain tumors
  • Contains critical discussions on the potential and limitations of neuroimaging as a translational tool for the diagnosis and treatment of brain tumor and neuro-oncology patients
  • Presents an up-to-date reference on advanced imaging technologies, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), as well as the recent refinements in these techniques

Product Details

  • Published on: 2016-04-26
  • Original language: English
  • Number of items: 1
  • Dimensions: 10.90″ h x 1.80″ w x 8.60″ l, 6.68 pounds
  • Binding: Hardcover
  • 864 pages
WhatsApp WhatsApp us
%d bloggers like this: